Publications (151,536)

Search

Modulatory effects of apical and basolateral proteases on renal ENaC function

Bertog M, Korbmacher C (2019)

Conference contribution

Effects of syntaxin 2, 3, and 4 on rat and human epithelial sodium channel (ENaC) in Xenopus laevis oocytes

Rauh R, Frost F, Korbmacher C (2019)

Conference contribution

Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. (2019)

Conference contribution

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB)

Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. (2019)

Conference contribution

KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. (2019)

Conference contribution

Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study

Tesch H, Loibl S, Kast K, Jackisch C, Moebus V, Buchen S, Untch M, et al. (2019)

Conference contribution

Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)

Furlanetto J, Nekljudova V, Schneeweiss A, Thode C, Denkert C, Untch M, Bassy M, et al. (2019)

Conference contribution

PRECYCLE Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, Witzel I, et al. (2019)

Conference contribution

Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials

Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. (2019)

Conference contribution

Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy

Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. (2019)

Conference contribution

‹ 1 ... 5,171 5,172 5,173 5,174 5,175 ... 15,154 ›